Advertisement

Topics

Investigators Still Seeking Options Beyond PARP Inhibitors in Ovarian Cancers

17:33 EST 18 Jan 2019 | OncLive

Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.

Original Article: Investigators Still Seeking Options Beyond PARP Inhibitors in Ovarian Cancers

NEXT ARTICLE

More From BioPortfolio on "Investigators Still Seeking Options Beyond PARP Inhibitors in Ovarian Cancers"

Advertisement
Quick Search
Advertisement
Advertisement